Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes? - Wikidata - wikimedia - TriplyDB

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

http://www.wikidata.org/entity/Q55514103

about

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

http://www.wikidata.org/entity/Q55514103

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh

2018年學術文章

@zh-hant

name

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

@en

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

@nl

type

label

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

@en

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

@nl

prefLabel

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

@en

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

@nl

P1433

Q55514103-897517AB-26AB-4D58-926B-A7CA4431AB47

P1476

Q55514103-7408F786-491F-4053-AE11-CC3360CE32DB

P2093

Q55514103-0E2DEDFE-D883-4771-8A53-869CA62AC2B0

Q55514103-348358BA-AC6E-42C9-98A6-726B57DAAC55

Q55514103-5CC4DAFE-8D80-495B-8AE7-19A61972CBA9

Q55514103-5FB71CD3-BA90-42DC-AF30-C0D6F770EAA7

Q55514103-6EF33AE2-D3C4-4522-B3F2-3CAB4620EA37

Q55514103-70FD918F-9EBA-457E-9209-F3C3916D7E66

Q55514103-B174B607-86AD-47F3-B174-588461A8280D

P2860

Q55514103-155FD7BF-848C-42ED-B792-22B4F7216B3A

Q55514103-1944A03B-3448-4CAD-9EF6-B7FBBEF7974B

Q55514103-1FE36636-04FB-4A64-8DEB-BC7491E46A61

Q55514103-2A178E1C-FC8E-4DB8-99FC-8E58F2612F6E

Q55514103-6477E6C3-8AF9-4832-9E34-8859680F7DCD

Q55514103-711F0958-B79F-40D9-9CEA-62891FCC0F33

Q55514103-835175FB-C468-438D-ADE6-F69A088C7DF9

Q55514103-9E2DB465-053F-4751-8D88-3B6191C1F1A2

Q55514103-ACC2BC37-B487-40FB-B98F-43ED0CC03A94

Q55514103-AEF7496B-04EC-4B5E-878D-EED13DA7FAE1

P304

Q55514103-CF2A9586-1CA7-418E-B0E2-925BF0213855

P31

Q55514103-131835FA-4D05-4D04-9AFC-1FD886431F09

P356

Q55514103-4336ED5C-9A79-43D8-B5B1-F23FEDA8111B

P433

Q55514103-6B59E5E1-DA11-419D-BC92-38C36B00E0F8

P478

Q55514103-D29B4E08-CC38-4FA1-9FA2-89D82E6E1F3A

P577

Q55514103-4CEEC01E-D248-4F60-9FB5-85A5DD5FBD42

P698

Q55514103-C8B1DFED-9F91-4AEC-A592-222CE4EB24AC

P932

Q55514103-E9FA3CD2-7BCB-4733-B929-98F9C9D003AB

P356

P1433

Open forum infectious diseases

P1476

Can the Ceftriaxone Breakpoints Be Increased Without Compromising Patient Outcomes?

@en

P2093

Anthony Harris

http://www.w3.org/2001/XMLSchema#string

Divya Rayapati

http://www.w3.org/2001/XMLSchema#string

Ebbing Lautenbach

http://www.w3.org/2001/XMLSchema#string

Jennifer H Han

http://www.w3.org/2001/XMLSchema#string

Pranita D Tamma

http://www.w3.org/2001/XMLSchema#string

Sara E Cosgrove

http://www.w3.org/2001/XMLSchema#string

Virginia M Pierce

http://www.w3.org/2001/XMLSchema#string

P2860

Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extended-spectrum beta-lactamases: implications for the clinical microbiology laboratory.

Treatment of infections with ESBL-producing organisms: pharmacokinetic and pharmacodynamic considerations.

Background and rationale for revised clinical and laboratory standards institute interpretive criteria (Breakpoints) for Enterobacteriaceae and Pseudomonas aeruginosa: I. Cephalosporins and Aztreonam.

Determining the optimal ceftriaxone MIC for triggering extended-spectrum β-lactamase confirmatory testing.

Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species

Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically ill patients with ventilator-associated pneumonia.

Multi-centre evaluation of a phenotypic extended spectrum β-lactamase detection guideline in the routine setting.

Antibiotic therapy for Klebsiella pneumoniae bacteremia: implications of production of extended-spectrum beta-lactamases.

Evaluation of the MicroScan ESBL plus confirmation panel for detection of extended-spectrum beta-lactamases in clinical isolates of oxyimino-cephalosporin-resistant Gram-negative bacteria.

Carbapenemase-Producing Organisms: A Global Scourge!

P304

ofy139

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/OFID/OFY139

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

5

http://www.w3.org/2001/XMLSchema#string

P577

2018-06-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29992175

http://www.w3.org/2001/XMLSchema#string

P932

6022551

http://www.w3.org/2001/XMLSchema#string